image by: HWN

HWN Suggests

The Heavy Cost of Using Weight-Loss Drugs to Get Skinny

Some people are trading medical risks for the cultural reward of becoming thin—chasing a body ideal without always understanding the hidden cost. The question is: How should we think about rapid weight loss when the long-term side effects, both physical and psychological, are still coming into focus... Today, skinny can come via syringe, but that does not guarantee a healthy life. Before we chase thinness through medications we need to ask: Is the body broken, or is it the mirror we’re all looking into? Losing weight is a choice. But it should never be made because of society’s aesthetic obsession with thinness—or without knowing the full costs.

read full article

Featured

 GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more

GLP-1 drugs for diabetes and weight loss have proven to be very effective, but they do have side effects. Among those side effects is "Ozempic face," where skin on the face sags and wrinkles. "Ozempic face" was coined in reference one of these drugs, although any rapid weight loss can cause it.

 GLP-1 Side Effects: Are They Worth the Risk?

Discover the potential side effects of GLP-1 medications. Are the benefits worth the risks? Learn more about GLP-1s and make informed decisions about your health.

 The unintended side effects of popular weight loss drugs

You’ve probably heard a lot about Ozempic and Wegovy, the semaglutide wonder drugs for weight loss. Their newfound popularity with prescribers and online pharmacies has sparked a global shortage. Other diabetes medications are now also being repurposed for weight loss: On Wednesday, the FDA approved Zepbound, another version of Mounjaro, for chronic weight management.

Articles of Interest

A new era of weight loss: Mental health effects of GLP-1 drugs

Psychologists are helping patients manage body image, identity, and relationship changes.

Adverse Effects of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes. However, the use of this relatively new class of drugs may be associated with certain adverse effects. Concerns have been expressed regarding the effects of these drugs on pancreatic and thyroid tissue, since animal studies and analyses of drug databases indicate an association of GLP-1 receptor agonists with pancreatitis, pancreatic cancer, and thyroid cancer.

An Extreme Risk of Taking Ozempic: Malnutrition

People taking Ozempic tend to lose weight because they consume fewer calories, not because the drug itself magically burns fat, Dr. Gabbay said. If patients don’t regularly meet with their doctors to ensure they are getting adequate nutrition, these medications could lead to, or exacerbate, disordered eating, Dr. Kraftson said.

Anesthesia Risk Linked To GLP-1 Drugs, EU Warns—Here’s What​​ To Know About Aspiration

European medical officials advised patients taking GLP-1 weight loss and diabetes drugs who will be sedated for an upcoming surgery to warn their doctors about their medication use to avoid the risk of a rare respiratory complication called aspiration, a connection several other medical organizations have looked into in the past.

Common Side Effects of GLP-1 Weight Loss Medications

All of these side effects tend to be most common when you first start taking the medication or if your dose has been increased. Most GLP-1 side effects occur within the first week or two of starting on the weight loss drug and are usually mild to moderate. We won’t lie, many people report some significant discomfort as their body adjusts. The good news is these side effects tend to decrease and go away within the first two months.

Dealing With Unexpected Effects of GLP-1s

Nausea and stomach problems are well-known side effects of GLP-1s, but you may be less familiar with other pros and cons of these powerful medications.

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Our findings reveal that all evaluated GLP-1 RAs were associated with a significant increased risk of nausea. Notably, orforglipron exhibited the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. Nausea was the most frequently reported symptom, besides vomiting and diarrhea, findings consistent with prior research in diabetic populations

GLP-1 Weight Loss Drugs: Be Aware of These Severe Side Effects

Losing weight can be a really difficult journey for many, and with the advent of GLP-1 weight loss drugs, there seems to be a promising aid on the horizon. However, like any medication, GLP-1 drugs come with their share of potential side effects.

Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks

While GLP-1RAs are effective in managing obesity, their use is associated with gastrointestinal side effects and rare but serious adverse events. The findings underscore the importance of individualized dosing and thorough patient assessment.

How to Tame GLP-1 Side Effects: 6 Tips

For some people, GLP-1 meds can work wonders. They help lower blood sugar (glucose) and manage type 2 diabetes. They also help people with obesity manage their weight. But like many multitasking meds, it's not all sunshine. GLP-1 side effects can come along and spoil the fun.

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

Ozempic Could Be Blinding People Trying to Lose Weight

All three studies showed a link between GLP-1 medications like Ozempic and a rare eye disorder called non-arteritic anterior ischemic optic neuropathy, or NAION, for short. It causes sudden and permanent vision loss. NAION is caused by a reduction in blood flow to the optic nerve

Ozempic teeth: Dentists warn of new GLP-1 side effect

Unlike some other GLP-1 side effects, the damage to your teeth may not be reversible if you stop taking the medication. One simple way to prevent “Ozempic teeth” is to drink more water, advises Taylor. Chewing sugar-free gum can also boost your saliva production if you’re experiencing dry mouth as a result of the medication.

Side effects of GLP-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising treatment for obesity and diabetes. Over the past few years, recognition has grown of their transformational potential for the more than one billion people living with obesity and over 800 million with diabetes globally. However, appreciation of the risks is critical to inform evidence based discussions. The potential harms associated with GLP-1 receptor agonists can be broadly categorised into those that are well known, rare events in which the causal association is weaker or uncertain, and emerging side effects or those with hypothesised links that are still being investigated.

Study identifies benefits, risks linked to popular weight-loss drugs

GLP-1 medications tied to decreased risk of dementia, addiction; increased risk of kidney, pancreas and gastrointestinal problems.

The Health Risks and Benefits of Weight-Loss Drugs

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.

The pregnancy risks of Ozempic and Wegovy need more attention

The drugs are linked to birth defects in animal studies. Why is this information so hard to find?

The Risks of Taking Drugs Like Ozempic When You’re Over 65

There are few constants within the world of weight loss, but one concept holds up: No matter how you lose weight — through restrictive eating, bariatric surgery or the new, buzzy class of injectable medications like Ozempic and Wegovy — you’re also probably shedding muscle. That’s particularly a concern for older adults, obesity medicine experts say. The more muscle someone over the age of 65 loses, the greater their risk of becoming frail or suffering a fracture or fall (which can be fatal in older adults). It is crucial for older adults to maintain muscle mass so that they can stay mobile and independent.

Weight loss jabs and cancer risk: here’s what you need to know about the research so far

The overall cancer risk associated with GLP-1 drugs and tirzepatide appears to be low. But it’s important to emphasise that these medications are not recommended for people with a personal or family history of certain types of thyroid cancer, or also endocrine conditions such as multiple endocrine neoplasia syndrome, because these conditions may increase sensitivity to hormone-related tumour growth.

Weight-Loss Drugs Like Wegovy Are Linked to Hair Loss

There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds, lower heart-disease risk, manage obstructive sleep apnea, and more. But as more people use these drugs, which target hormones including GLP-1, doctors are learning more about the potential downsides, as well. In the latest study published on MedRxiv—a site that hosts early research not yet peer reviewed by experts—scientists in Canada report that using GLP-1 drugs can contribute to a higher risk of hair loss, especially among women.

Resources

Hundreds of weight loss and diabetes jab users report pancreas problems

Although there is no known genetic link that increases the risk of acute pancreatitis while taking GLP-1 medicines, the MHRA said: “Sometimes genes can influence the side-effects an individual experiences when taking a medicine, so in the context of the increasing usage of these medicines and the reports of acute pancreatitis we have received, we are exploring this further.”